Repertoire Genesis Incorporation;Hyogo College Of Medicine
发明人:
申请号：
EP18768584.7
公开号：
EP3597766A1
申请日:
2018.03.14
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention provides a technique for predicting an effective patient prior to starting cancer immunotherapy. The present invention provides a method of using T cell receptor (TCR) diversity of a subject as an indicator of responsiveness of the subject to cancer immunotherapy. The present invention also provides a composition for treating cancer in a subject with high TCR diversity of T cells, comprising an immune checkpoint inhibitor. The present invention is also directed to a companion medicament using such TCR diversity.
